Your session is about to expire
← Back to Search
18F-DCFPyL PET/CT Scan for Prostate Cancer
Study Summary
This trial is testing a new way to find prostate cancer that may be more accurate than current methods.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 & 3 trial • 385 Patients • NCT02981368Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received an IV dye for an X-ray less than a day before my PET/CT scan.I had a radioisotope treatment within a specific timeframe before my PET/CT scan.I am 18 years old or older.I have chosen to have a prostate biopsy guided by ultrasound.My cancer is in an early stage, as found by a physical exam.
- Group 1: 18F-DCFPyL Injection
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being welcomed into this clinical trial?
"This trial is currently not accepting new patients, as the final edit was made on April 5th 2022. However, if you are looking for other studies related to prostate cancer, 1,321 trials have opened their doors to participants and 18 such trials concern 18F-DCFPyL Injection."
To what degree is 18F-DCFPyL Injection a risk to human health and wellbeing?
"According to our team's assessment, 18F-DCFPyL Injection scored a 2 on the safety scale since there is some evidence of its security but none detailing any efficacy."
Could you elucidate on other experiments that have utilized 18F-DCFPyL Injection?
"Currently, there are 18 studies ongoing researching the efficacy of 18F-DCFPyL Injection with none in Phase 3. Primarily based out of Baltimore, Maryland; however, a total of 27 locations across the nation are conducting research for this drug."
What therapeutic applications is 18F-DCFPyL Injection being applied to?
"18F-DCFPyL Injection is commonly utilized for the management of elevated serum prostate specific antigen (psa). It can also benefit those affected by suspected metastasis, positron emission tomography imaging, and recurrent prostatic carcinoma."
Is there opportunity for new participants in this investigation?
"The details published on clinicaltrials.gov confirm that this research is not recruiting participants at present, with the initial posting taking place on March 29th 2018 and the most recent update being April 5th 2022. Nevertheless, there are over 1300 other medical studies which currently have open enrollment options available."
Share this study with friends
Copy Link
Messenger